Breaking News
Investing Pro 0
New Year’s SALE: Up to 40% OFF InvestingPro+ CLAIM OFFER
Close

Gilead Sciences Inc (GGILD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
76.90 -0.41    -0.53%
27/01 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 490
  • Bid/Ask: 76.90 / 77.07
  • Day's Range: 76.29 - 77.05
Type:  Equity
Market:  Italy
ISIN:  US3755581036 
Gilead 76.90 -0.41 -0.53%

GGILD Recent Sentiments

 
This page features our users' sentiments regarding the Gilead share. Assess users' predictions on whether they expect Gilead shares to be bearish or bullish.
Start Date Username Call Open Rate End Date Chg. %
Jan 03, 2023 Luigi Luperi   81.56 Jan 27, 2023 @ 76.90 -5.71%
Dec 19, 2022 Adriano Rossi   81.89 Jan 13, 2023 @ 81.02 +1.06%
Nov 07, 2022 Max Arnaboldi   80.10 Dec 02, 2022 @ 82.87 +3.46%
Nov 01, 2022 Francesco Venturini   78.78 Nov 28, 2022 @ 82.84 +5.15%
Oct 31, 2022 paolo solinas   78.88 Nov 11, 2022 @ 77.91 +1.23%
Oct 28, 2022 paolo solinas   78.22 Oct 29, 2022 @ 78.22 0.00%
Oct 12, 2022 Luigi Luperi   67.83 Nov 04, 2022 @ 81.09 +19.55%
Aug 16, 2022 Francesco Venturini   64.68 Sep 09, 2022 @ 65.35 +1.04%
Aug 16, 2022 Enzo Amato   65.25 Sep 09, 2022 @ 65.35 +0.15%
Aug 16, 2022 Zainetto Fiscale   65.25 Aug 16, 2022 @ 65.20 +0.08%
Aug 16, 2022 Gp Z   65.25 Sep 09, 2022 @ 65.35 +0.15%
Jul 07, 2022 Marco Forte   61.61 Jul 11, 2022 @ 62.47 +1.40%
Aug 17, 2021 Vincenzo Palumbo   60.61 Aug 23, 2021 @ 62.07 +2.41%
Aug 11, 2021 Luigi Mazzanti   59.00 Sep 03, 2021 @ 60.77 +3.00%
Aug 11, 2021 Ferdinando Trovato   58.93 Aug 16, 2021 @ 60.61 +2.85%
Jun 09, 2021 Andrea Perrucchietti   55.55 Jun 14, 2021 @ 55.70 +0.27%
Jun 09, 2021 Andrea Perrucchietti   55.55 Jun 14, 2021 @ 55.70 +0.27%
May 24, 2021 Andrea Perrucchietti   56.62 May 31, 2021 @ 54.55 -3.66%
May 15, 2021 Andrea Perrucchietti   56.61 May 17, 2021 @ 56.97 +0.64%
May 03, 2021 Marco Burroni   53.02 May 28, 2021 @ 54.36 +2.53%
Apr 30, 2021 FABIO MAFFEIS   51.66 May 03, 2021 @ 53.99 +4.51%
Apr 30, 2021 FABIO MAFFEIS   51.66 May 03, 2021 @ 53.99 +4.51%
Apr 30, 2021 FABIO MAFFEIS   51.66 May 03, 2021 @ 53.99 +4.51%
Apr 21, 2021 alby mariani   54.45 May 14, 2021 @ 56.61 -3.97%
Mar 08, 2021 Marco Burroni   53.33 Apr 02, 2021 @ 56.53 +6.00%
Mar 05, 2021 Marco Chiossone   52.95 Mar 26, 2021 @ 54.68 +3.27%
Feb 22, 2021 Antonio Salcuni   53.80 Mar 19, 2021 @ 53.97 +0.32%
Feb 11, 2021 Luigi Mazzanti   55.39 Mar 05, 2021 @ 53.33 -3.72%
Feb 09, 2021 Gianni Palmeri   55.84 Mar 05, 2021 @ 53.33 -4.49%
Feb 02, 2021 Paolo Vercellino   54.05 Feb 26, 2021 @ 51.00 -5.64%
Jan 26, 2021 Marco Chiossone   55.97 Feb 19, 2021 @ 53.80 -3.88%
Jan 26, 2021 Giovanni Bertuzzi   55.90 Feb 08, 2021 @ 56.96 +1.90%
Jan 20, 2021 Antonio Salcuni   55.93 Feb 12, 2021 @ 55.19 -1.32%
Jan 19, 2021 maffeo schiavi   55.68 Feb 12, 2021 @ 55.19 -0.88%
Jan 18, 2021 Marco Burroni   52.65 Feb 12, 2021 @ 55.19 +4.82%
Jan 05, 2021 Luigi Luperi   48.98 Jan 29, 2021 @ 53.89 +10.02%
Jan 05, 2021 Erik Lagolio   49.20 Jan 29, 2021 @ 53.89 +9.53%
Jan 04, 2021 Gio Mal   48.11 Jan 29, 2021 @ 53.89 +12.01%
Jan 04, 2021 Luigi Parisi   48.11 Jan 29, 2021 @ 53.89 +12.01%
Dec 29, 2020 Vincenzo De Rosa   46.63 Jan 05, 2021 @ 48.65 +4.33%
Dec 28, 2020 Alex Mez   46.48 Jan 22, 2021 @ 54.94 -18.20%
Dec 28, 2020 Ale Pellicano   46.53 Jan 22, 2021 @ 54.94 +18.07%
Dec 23, 2020 Marco Burroni   47.08 Jan 15, 2021 @ 52.24 +10.96%
Dec 21, 2020 FABIO CERGNUL   48.16 Jan 15, 2021 @ 52.24 +8.47%
Dec 18, 2020 Andrea Fulghieri   47.96 Jan 08, 2021 @ 51.47 -7.32%
Dec 15, 2020 maffeo schiavi   49.24 Jan 08, 2021 @ 51.47 -4.53%
Dec 01, 2020 Gio Mal   51.29 Dec 25, 2020 @ 47.00 -8.36%
Nov 23, 2020 damiano beccari   50.70 Dec 18, 2020 @ 48.01 -5.31%
Nov 20, 2020 Marco Burroni   49.91 Dec 11, 2020 @ 49.78 -0.26%
Nov 18, 2020 Gianni Gioda   51.46 Dec 11, 2020 @ 49.78 -3.26%
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GILD Comments

Write your thoughts about Gilead Sciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Oc Masai
Oc Masai Apr 27, 2021 7:54
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good job GILD. bullish move forward
Ashraf Elgendy
Ashraf Elgendy Mar 07, 2021 13:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Kite, a unit of Gilead Sciences (GILD),has announced that theFDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults...
RM RM
RM RM Mar 01, 2021 21:53
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Up Again
Ken Laing
Ken Laing Oct 23, 2020 18:43
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Time to load up before the big rise coming next week
Iggy Maldon
Iggy Maldon Jul 30, 2020 20:22
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Classic pump n’ dump. What a shambles
RM RM
RM RM May 28, 2020 22:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Will reach above 95
Chili Daug
Chili Daug May 28, 2020 22:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
when? hahah
SAGAR AGARWAL
SAGAR AGARWAL May 15, 2020 14:52
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good time to accumulate.
Khizer Malik
Khizer Malik May 14, 2020 11:04
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Gilead will be supplying remdesivir to 127 countries starting next week! Also backed by big government organisations including donald trump. Good investmenr
Willy Chin
Willy Chin Apr 23, 2020 18:14
Saved. See Saved Items.
This comment has already been saved in your Saved Items
High chance to be trading above 90, good long stock
Viktor Veselý
Viktor Veselý Apr 12, 2020 7:48
Saved. See Saved Items.
This comment has already been saved in your Saved Items
By Deena Beasley(Reuters) - More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation.The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included -- in one case because of a dosing error.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email